Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN to Brazil.
A team from Precisa Medicamentos visited the Bharat Biotech facility last week to discuss potential export possibilities of COVAXIN, India’s indigenous vaccine for COVID-19. The team met Dr Krishna Ella at Bharat Biotech on Jan 7-8, 2021 at the Bharat Biotech facility in Genome Valley, Hyderabad. During the discussion, André Aranha Corrêa do Lago, Ambassador of Brazil to India, joined on a virtual platform. In principle, it is understood between both parties that supplies of COVAXIN to be prioritised for the public market, through a direct procurement by the Government of Brazil. Supplies to the private market would be based upon receipt of market authorisation from ANVISA, the Brazilian regulatory authority.
Dr Krishna Ella, Chairman and MD, Bharat Biotech said, “COVAXIN is an innovation and a perfect example of novel product development from India. Our goal for all vaccines developed at Bharat Biotech is to provide global access to populations that need it the most. COVAXIN has generated excellent safety data with robust immune responses to multiple viral proteins that persist. We are happy to note that vaccines innovated in India are able to address the public health needs of Brazil. ”
After the technical visit to Bharat Biotech’s Genome Valley facility in Hyderabad, the pharma director of Precisa Medicamentos, Emanuela Medrades said “We identified highly technological, scientific and sanitary control levels. There were also excellent outcomes in clinical trials, which will be published soon. Bharat Biotech has exceeded our expectations, demonstrating quality and safety at the level of the largest vaccine suppliers in the world.”
COVAXIN is a highly purified and inactivated two-dose SARS-CoV-2 vaccine, manufactured in a Vero cell manufacturing platform.